Introduction: Myelodysplastic syndrome (MDS) is a diverse and complex hematological disease. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with myelodysplastic syndrome. the authors present this report in order to provide results and some experience in HSCT for MDS. Case report. Two cases who were in intermidiate-2 and high risk group (IPSS) underwent peripheral stem cell transplantation. Pretransplant treatment was induction chemotherapy with 7và 3 protocol. One patient who failed to response to 7và 3 protocol received four cycles of Decitabine. Bu/Cy was used as conditioning regimen. Time to neutrophil and platelet recovery were 14-15 days and 16-23 days, respectively. Acute complications consisted febrile neutropenia, drug-induced hepatitis and CMV reactivation. All patients had grade II chronic GVHD. One patient relapsed and transformed to acute myeloid leukemia. However, she recovered her good response after withdrawal of immunosuppressive drugs. Recently, two patient were still alive and achieved durable complete remission. Conclusion : It is possible to apply peripheral stem cell transplantation in MDS broadly in order to expand survival for patients. GVL effect is very important to prevent disease from relapse after transplantation.